- 1 **TITLE:** Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subjects.
- 2
- 3 **RUNNING TITLE:** SARS-CoV-2 antibodies in recovered COVID-19 subjects.
- 4

5 AUTHOR LIST:

- 6 Huynh, Angela¹; Arnold, Donald M.^{1,2}; Smith, James W.¹; Moore, Jane C.¹; Zhang, Ali ^{3,4,5};
- 7 Chagla, Zain^{1,6}; Harvey, Bart J.^{7,8}; Stacey, Hannah D.^{3,4,5}; Ang, Jann C.^{3,4,5}; Clare, Rumi¹; Ivetic,
- 8 Nikola¹; Chetty, Vasudhevan T.⁹; Bowdish, Dawn ME^{1,3,4}; Miller, Matthew S.^{3,4,5}; Kelton, John
- 9 G.^{1,2}; Nazy, Ishac^{1,2}

10

11 AFFILIATE INSTITUTIONS:

¹Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, 12 Hamilton, Ontario, Canada; ²McMaster Centre for Transfusion Research, Hamilton, Ontario, 13 Canada; ³Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, Ontario, 14 15 Canada; ⁴McMaster Immunology Research Centre, Hamilton, Ontario, Canada; ⁵Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; 16 ⁶Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, 17 Ontario, Canada; ⁷Hamilton Public Health Services, Hamilton, Ontario, Canada; ⁸Dalla Lana 18 School of Public Health, University of Toronto, Toronto, Ontario, Canada; ⁹HRLMP McMaster 19 20 University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

22 CORRESPONDENCE AUTHOR(S):

23	Ishac Nazy, PhD
24	HSC 3H53
25	1280 Main Street West
26	Hamilton, ON, Canada L8S 4K1
27	Tel: (905) 525-9140 x20242
28	Fax: (905) 529-6359
29	Email: <u>nazii@mcmaster.ca</u>
30	
31	Abstract word count: 200
32	Main text word count: 3487
33	Table and Figures: 2 Tables and 4 Figures
34	References: 47

36 Abstract:

37	Coronavirus Disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute
38	respiratory syndrome coronavirus 2 (SARS-CoV-2). While detection of SARS-CoV-2 by
39	polymerase chain reaction with reverse transcription (RT-PCR) is currently used to diagnose
40	acute COVID-19 infection, serological assays are needed to study the humoral immune response
41	to SARS-CoV-2. SARS-CoV-2 IgG/A/M antibodies against SARS-CoV-2 spike (S) protein and
42	its receptor-binding domain (RBD) were characterized using an enzyme-linked immunosorbent
43	assay (ELISA) and assessed for their ability to neutralize live SARS-CoV-2 virus in recovered
44	subjects who were RT-PCR-positive (n=153), RT-PCR-negative (n=55), and control samples
45	collected pre-COVID-19 (n=520). Anti-SARS-CoV-2 antibodies were detected in 90.9% of
46	resolved subjects up to 180 days post-symptom onset. Anti-S protein and anti-RBD IgG titers
47	correlated (r = 0.5157 and r = 0.6010, respectively) with viral neutralization. Of the RT-PCR-
48	positive subjects, 22 (14.3%) did not have anti-SARS-CoV-2 antibodies; and of those, 17 had
49	RT-PCR cycle threshold (Ct) values >27, raising the possibility that these indeterminate results
50	are from individuals who were not infected, or had mild infection that failed to elicit an antibody
51	response. This study highlights the importance of serological surveys to determine population-
52	level immunity based on infection numbers as determined by RT-PCR.

53

54 Keyword: SARS-CoV-2, COVID-19, antibody, serology

56 Introduction:

57	Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory
58	syndrome coronavirus 2 (SARS-CoV-2) [1]. Asymptomatic and pre-symptomatic virus
59	transmission is one of the biggest challenges with the global pandemic [2]. It is estimated up to
60	80% of people infected with COVID-19 have none or mild symptoms and asymptomatic
61	transmission accounts for half of all COVID-19 infections [3-5]. Approximately 20% of
62	symptomatic infections are severe, disproportionately impacting the elderly and patients with
63	underlying health conditions [6, 7].
64	Laboratory diagnosis of COVID-19 is made using polymerase chain reaction with reverse
65	transcription (RT-PCR) to detect viral mRNA from nasal or throat swabs [8-11]. Viral RNA is
66	detectable as early as the first day of symptom onset and peaks within the first week of symptom
67	onset [9]. The SARS-CoV-2 spike (S) protein, specifically the receptor-binding domain (RBD),
68	facilitates viral entry into the cell via the angiotensin-converting enzyme-2 (ACE2) receptor on
69	host cells [12-15]. Most people with a confirmed RT-PCR diagnosis of SARS-CoV-2 infection
70	develop IgG, IgA and IgM antibodies against S protein within 1–2 weeks of symptom onset and
71	continue to circulate after initial viral clearance [16-21].
72	Serological studies have shown IgG antibodies to SARS-CoV-2 S protein and RBD are
73	detected in the circulation of greater than 90% of infected subjects by 10-11 days post-symptom
74	onset [16, 18, 20, 22] Virus specific neutralizing antibadies, either induced through infection or

onset [16, 18, 20, 22]. Virus-specific neutralizing antibodies, either induced through infection or

vaccination, can block viral infection [23]. Although antibodies may be generated against

76 multiple domains within the S protein, most neutralizing antibodies and highly potent

monoclonal antibodies target the RBD [15, 24]. In this report, we profile the IgG, IgA, and IgM

78 responses to the SARS-CoV-2 S protein and RBD in a cross-sectional serological study

79 involving resolved COVID-19 infection. We also compared antibody levels with viral

- 80 neutralization and RT-PCR results.
- 81

82 Methods and Materials:

83 Study Design

84 Subjects who recovered from COVID-19 infection were identified by treating physicians, public

85 health officials and through hospital discharge databases that included hospitals in Hamilton,

86 Ontario, Canada (Hamilton General Hospital, Juravinski Hospital, McMaster University Medical

87 Centre, and St. Joseph's Healthcare). The study inclusion criteria were ≥ 18 years of age, either

testing positive or negative for COVID-19 in the RT-PCR, with no exclusion criteria.

89 Participants with RT-PCR-positive results for SARS-CoV-2 and had since recovered (resolved

90 RT-PCR-positive, n=153), and subjects who experienced symptoms but tested negative by RT-

91 PCR (RT-PCR-negative, n=55) were included. Participants were interviewed by phone and self-

92 reported their age, sex, symptom onset date and RT-PCR test date and result. Pre-COVID-19

93 control samples were selected from healthy donors (n=37) and samples sent for the ITP Registry

biobank from the McMaster Platelet Immunology Laboratory drawn prior to November 2019

95 (pre-COVID-19, n=483) before documented local community transmission of SARS-CoV-2.

96 Serum was collected by venipuncture and cryopreserved until use. This study was approved by

97 the Hamilton Integrated Research Ethics Board (HIREB) and written informed consent was

98 obtained from all participants.

99 Production of recombinant SARS-CoV-2 S protein and RBD

A detailed protocol outlining protein production can be found in a study by Stadlbauer *et al* [25]
and is outlined in the Supplemental methods.

- 102 *Measuring SARS-CoV-2 antibodies*
- 103 Microtitre well plates (384 wells, Nunc Maxisorp, Rochester, NY, USA) were coated with

104 25µL/well of S protein (5µg/mL) or RBD (2µg/mL) suspended in 50 mM carbonate-bicarbonate

105 buffer (pH 9.6). The plates were then blocked with 100µL/well of 3% skim milk prepared in

106 phosphate buffered saline (PBS) with 0.05% Tween 20 at room temperature for 2-hours. The

107 blocking solution was removed, and diluted serum samples (1/100 prepared in 1% skim milk in

108 PBS/0.05% Tween 20) in technical duplicates were added to the plates and incubated for 1-hour

109 at room temperature. The plates were washed twice with PBS/0.05% Tween 20 and thrice with

110 PBS. Bound human antibodies (IgG, IgA, or IgM) were detected with 25µL/well of alkaline

111 phosphatase conjugated goat anti-human IgG (γ -chain-specific, 1/2000, Jackson

112 ImmunoResearch Laboratories, Inc, Westgrove, PA, USA), goat anti-human IgA (α-chain-

specific; 1/500, Jackson ImmunoResearch Laboratories, Inc, Westgrove, PA, USA) antibody, or

114 goat anti-human IgM (μ-chain-specific; 1/1000, Jackson ImmunoResearch Laboratories, Inc,

115 Westgrove, PA, USA) antibody prepared in PBS/0.05% Tween 20 with 1% skim milk. Plates

116 were washed as before and followed with the addition of 50µL substrate (4-

117 nitrophenylphosphate disodium salt hexahydrate in diethanolamine (MilliporeSigma, St. Louis,

118 MO, USA). The optical density (OD) was read at 405nm and 490nm (as a reference) measured

using a BioTek 800TS microplate reader (BioTek, Winooski, VT, USA). The assay cut-off was

- 120 determined as the mean and 3 standard deviations (SD) of the pre-COVID-19 control population.
- 121 Data are shown as a ratio of observed OD to the determined assay cut-off OD. OD ratio values
- 122 above 1 ratio were considered positive in the SARS-CoV-2 ELISA. Results for optimization of

- 123 antigens, serum concentrations for the ELISA and its comparisons to commercially available
- assays can be found in the Supplemental data.
- 125 PCR Cycle threshold (Ct) values of resolved COVID-19 samples
- 126 RT-PCR Ct values were retrieved from a subset of resolved subjects' original test date RT-PCR
- 127 (n=54). A detailed protocol of the in-house RT-PCR run by the Hamilton Regional Laboratory
- 128 Medicine Program virology lab is outlined in the Supplemental methods.
- 129 Detecting neutralizing antibodies for SARS-CoV-2
- 130 Vero E6 cells (ATCC CRL-1586) were seeded at a density of 2.5×10^4 cells per well in opaque 96
- 131 well flat-bottom plates (Costar) in complete DMEM (supplemented with 10% FBS, 1% L-
- 132 glutamine, 100U/ml penicillin-streptomycin). After 24-hours of incubation, serum (resolved and
- 133 RT-PCR-negative subjects) was inactivated by incubating at 56°C for 30 minutes, then diluted
- 134 1:10 in low serum DMEM (supplemented with 2% FBS, 1% L-glutamine, 100U/mL penicillin-
- streptomycin), followed by a 1:2 dilution series in 96 well U-bottom plates resulting in a final
- 136 volume of 55µL diluted serum per well. An equal volume of SARS-CoV-2/SB3-TYAGNC
- 137 consisting of 330 PFU per well was then added to the diluted serum and the serum-virus mixture
- 138 was incubated at 37°C for 1-hour. Next, the Vero E6 culture media was then replaced with 100
- 139 μ L of the serum-virus mixture and was incubated at 37°C for 72-hours. The plates were read by
- 140 removing 50µL of culture supernatant and adding 50µL of CellTiter-Glo 2.0 Reagent (Promega,
- 141 G9243) to each well. The plates were then shaken at 282cpm at 3 mm diameter for 2-minutes,
- 142 incubated for 5-minutes at room temperature and luminescence was read using a BioTek
- 143 Synergy H1 microplate reader with a gain of 135 and an integration time of 1-second. Results are
- 144 expressed as geometric microneutralization titers at 50% (MNT50).
 - 7

145 Statistical Analyses

146	Descriptive statistics were used to summarize the IgG, IgA, and IgM binding to S protein and
147	RBD as measured by mean OD across antigen and technical replicates. Differences between data
148	were tested for statistical significance using the paired or unpaired t-test and the Mann-Whitney
149	test. P-values are reported as 2-tailed. Correlations were calculated using standard Pearson
150	correlation. All statistical analyses were conducted using GraphPad Prism (version 7.0a,
151	GraphPad Software, San Diego, USA).
152	
153	Results:
154	Study Demographics
155	Resolved (RT-PCR-positive, n=153) samples were collected between 7-211 days post-symptom
156	onset. Median age of the resolved RT-PCR-positive subjects was 49 years (range: $18 - 82$) and
157	95 subjects (62.1%) were female. COVID-19 negative subjects (RT-PCR-negative, n=55)
158	samples were collected between 7-246 days post-symptoms (Table 1). The median age of the
159	RT-PCR-negative subjects was 49 years (range: 20 – 89) and 39 (70.9%) were female (Table 1).
160	Eleven (7.2%) of the RT-PCR-positive resolved subjects and 37 (67.3%) of the RT-PCR-
161	negative subjects were asymptomatic before testing.
162	Detecting SARS-CoV-2 antibodies in resolved COVID-19 subjects
163	To study the antibody response to SARS-CoV-2, we tested for IgG, IgA, and IgM antibodies to

- the S protein and RBD in pre-COVID-19 controls (n=520), resolved COVID-19 subjects
- 165 (n=153), and RT-PCR-negative subjects (n=55). Pre-COVID-19 controls (n=520) were used to
- 166 determine the background reactivity to the S protein and RBD using samples from individuals

167	drawn before COVID-19 (pre-November 2019). The cut-off was determined as the mean plus
168	3SD of the OD readings in the pre-COVID-19 control population. Most pre-COVID-19 controls
169	had only background reactivity for both the full-length S protein and RBD (IgG = 98.9% , n=
170	514/520 and 98.5%, $n = 512/520$ below established cut-off, respectively). Each antigen and
171	antibody class had a few pre-COVID-19 controls that tested positive for the antibodies based on
172	the determined cut-off. The majority of pre-COVID-19 controls that tested positive within the
173	groups had IgM against both S protein and RBD, 1.5% (n = $8/520$ testing antibody-positive) and
174	2.1% (n= $11/520$ antibody-positive), respectively. Some control samples were positive in the S
175	protein- and RBD-specific IgA assays: 1.3% ($n = 7/520$ antibody-positive) and 1.0% ($n = 5/520$
176	antibody-positive), respectively. Antigen concentration of S protein and RBD and serum
177	dilutions were optimized by testing known COVID-19-positive and pre-COVID-19 samples (see
178	Supplemental data).
178 179	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies
179	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies
179 180	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and
179 180 181	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and 22 (14.4%) did not have detectable antibodies against SARS-CoV-2. Of the 55 RT-PCR-negative
179 180 181 182	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and 22 (14.4%) did not have detectable antibodies against SARS-CoV-2. Of the 55 RT-PCR-negative subjects, three had reactivity to the SARS-CoV-2 antigens (5.5%, Table 2). Most resolved
179 180 181 182 183	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and 22 (14.4%) did not have detectable antibodies against SARS-CoV-2. Of the 55 RT-PCR-negative subjects, three had reactivity to the SARS-CoV-2 antigens (5.5%, Table 2). Most resolved subjects tested positive for anti-S protein and anti-RBD IgG (n=130/153 testing positive (85.0%)
179 180 181 182 183 184	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and 22 (14.4%) did not have detectable antibodies against SARS-CoV-2. Of the 55 RT-PCR-negative subjects, three had reactivity to the SARS-CoV-2 antigens (5.5%, Table 2). Most resolved subjects tested positive for anti-S protein and anti-RBD IgG (n=130/153 testing positive (85.0%) and n=119/153 testing positive (77.8%), respectively, Supplemental data). In addition, some of
179 180 181 182 183 184 185	Of the 153 resolved COVID-19 subjects tested, 131 (85.6%) tested positive for antibodies against SARS-CoV-2 (IgG, IgA, or IgM antibodies against the S protein or RBD, Table 2) and 22 (14.4%) did not have detectable antibodies against SARS-CoV-2. Of the 55 RT-PCR-negative subjects, three had reactivity to the SARS-CoV-2 antigens (5.5%, Table 2). Most resolved subjects tested positive for anti-S protein and anti-RBD IgG (n=130/153 testing positive (85.0%) and n=119/153 testing positive (77.8%), respectively, Supplemental data). In addition, some of the same resolved subjects also tested positive for anti-S protein IgA (60.1%, 92/153 antibody-

189	To further understand	RT-PCR-positive	COVID-19 subjects	that tested negative f	for anti-SARS-

- 190 CoV-2 antibodies, 22/153 (14.4%) resolved subjects were further investigated. The Ct values
- 191 from the initial RT-PCR test were obtained for 54/153 (35.3%) of the resolved participants,
- 192 including 18/22 (81.8%) who were RT-PCR-positive but antibody-negative. The Ct values for
- the RT-PCR-positive/antibody-negative subjects (n=18) ranged from 16.00 to 37.38, with a
- 194 mean of 32.29 ± 4.647 , whereas the mean of the subjects who were RT-PCR-positive/antibody-
- 195 positive was 22.92 ± 5.177 (range = 14.99 34.94, n=36, Figure 1A, 1B). Sera from 13 of 18
- 196 resolved subjects who tested RT-PCR-positive/antibody-negative were collected within 60 days
- 197 after initial RT-PCR test, within the reported optimal time for anti-SARS-CoV-2 antibodies
- 198 (Figure 1C) [18, 20, 21, 26].
- 199 During assay validation, 14 resolved subjects (9 antibody-positive and 5 antibody-negative) were
- 200 tested in the commercially available EUROIMMUN Anti-SARS-CoV-2 ELISA and the Ortho
- 201 Clinical Diagnostics COVID-19 IgG Antibody Test. There was 100% correlation between the
- 202 commercial reference assays and our in-house developed assays. Three of the 14 in validation
- 203 testing were RT-PCR-positive/antibody-negative and had high Ct value samples and were
- 204 confirmed to be negative for SARS-CoV-2 antibodies in the commercial reference assays
- 205 (Supplemental data).
- 206 Persistence of anti-S protein and anti-RBD antibodies in resolved subjects
- 207 IgG antibodies against S protein and RBD were detected in samples collected >120 days from
- symptom onset (Figure 2A)[5, 16, 18, 20]. Anti-S protein IgG was found in all resolved
- 209 participants collected between 60 and 120 days (23/153 resolved subjects). In the resolved
- 210 patients collected between 120 and 180 days from symptom onset, there was a decrease in the
- 211 percentage of antibody-positive samples when compared to the previous time bin (55/60

212 samples, 91.7%). Of the resolved subjects tested >180 days of symptom onset (n=11), 90.9% had 213 an anti-S protein IgG antibody. However, IgG levels against RBD demonstrated a 14.8% 214 decrease in subjects who were antibody-positive between 120-180 days when compared to the 215 groups before 120 days, and a 30% decrease in subjects with antibody after 180 days (Figure 216 2A). In contrast, IgA and IgM to both antigens were much less sustained (IgA - Figure 2B, IgM 217 - Figure 2C). After reaching a maximum in the 0–60 days bin, there was a clear and continuous 218 decline throughout the time series such that after 180 days, the anti-S protein and anti-RBD IgA 219 levels in subject groups declined by 30% and 80% respectively, while IgM levels for both 220 antigens declined by 90% (IgA - Figure 2B, IgM – Figure 2C).

221 Investigation of neutralizing SARS-CoV-2 antibodies

222 Neutralization potency was measured using a microneutralization assay with live SARS-CoV-2

virus. In all resolved subjects, the presence of high titers of anti-S protein and anti-RBD IgG

moderately correlated with higher titers of neutralizing antibodies (Figure 3A, 3B, r=0.5157,

225 p<0.0001 anti-S protein IgG and r=0.601, p<0.0001 anti-RBD IgG). Weaker correlations were

found between neutralizing antibody titers and anti-S protein IgA (r=0.4507), IgM (r=0.4443),

and anti-RBD IgA (r=0.3055), IgM (r=0.3365). Geometric MNT50s ranged from below

detection limit (MNT50 = 5) to MNT50=1280. Resolved subjects who were only antibody-

positive for anti-S protein IgG but not antibody-positive for anti-RBD IgG antibodies (n=11)

either had lower neutralizing antibody levels (mean MNT50 = 19.5, range 5 - 80) or were

undetectable. No temporal trends were observed based on this cross-sectional study of resolved

subjects, however neutralizing antibodies in resolved subjects were detected as far as 180 days

post-symptom onset (Figure 3C). After 180 days, 3/11 (27.3%) of subjects tested for neutralizing

antibodies had a level above MNT50=160.

235 SARS-CoV-2 antibody profile of asymptomatic, non-hospitalized, and hospitalized resolved
236 subjects

- 237 Of the 153 resolved subjects tested, eight (5.2%) were hospitalized for SARS-CoV-2 infection
- and were positive for anti-SARS-CoV-2 antibodies. All hospitalized subjects had detectable anti-
- RBD and anti-S protein IgG, and anti-S protein IgA antibodies in their serum (Figure 4A and
- 4B). The levels of anti-S protein and anti-RBD IgG (mean OD₄₀₅ ratio) in resolved subjects who
- 241 were hospitalized were significantly higher than the non-hospitalized resolved population (anti-S
- 242 protein IgG; 5.667±0.065 vs. 3.836±1.831, p<0.001; anti-RBD IgG 5.240±0.8483 vs.
- 243 2.758±1.730, p<0.001). All other antigen and antibody classes were not significantly different
- between hospitalized and non-hospitalized resolved subjects. When compared to resolved
- hospitalized subjects (range: 3.209 5.831), there was a larger spread in antibody levels in the
- 246 non-hospitalized population (range: 0.1508 5.828; Figure 4).
- 247 Of the resolved COVID-19 study participants collected, 11 (7.2%) were asymptomatic. Six of
- the 11 (54.5%) asymptomatic subjects did not produce any anti-S protein or anti-RBD antibodies
- 249 (Figure 4). Six of the asymptomatic subjects were in the category of RT-PCR-positive/antibody-
- 250 negative with a high Ct value.
- 251

252 Discussion:

- 253 Understanding the characteristics of the SARS-CoV-2 antibodies will inform on the
- seroprevalence in communities and portions of the COVID-19 immune response. We describe
- 255 initial cross-sectional results of our longitudinal study of quantitative and functional SARS-CoV-
- 256 2 antibodies in resolved subjects. The expression of IgG, IgA and IgM antibodies reactive to the
- 257 immunogenic S protein and the RBD varied based on infection of SARS-CoV-2, severity of the

disease, and time delay from onset of symptoms to blood draw. We also observed temporal and
functional differences in anti-SARS-CoV-2 antibodies based on Ig classes and antigen.

260	Antibodies to SARS-CoV-2 were found in 131/153 (85.6%) subjects who tested positive
261	in the RT-PCR. In 22 of 153 (14.4%) resolved subjects who tested RT-PCR-positive, no
262	antibodies against SARS-CoV-2 were detected, which prompted further investigation using Ct
263	values. Of 18 samples of whom Ct values were available, 17 had high Ct values (32.29 ± 4.647 ,
264	range = 16.00 to 37.38, Figure 1D). The variation in antibody response in RT-PCR-positive
265	subjects may be due to multiple contributing factors including the size of the viral inoculum, the
266	genetic background of patients, and the presence of concomitant pathological conditions [27].
267	Studies have reported that after COVID-19 infection in some subjects, no antibodies can be
268	detected in circulation either because they have waned quickly, or that their immune response is
269	dependent on T cell responses [28-30]. Another factor is disease severity in the detection of
270	SARS-CoV-2 antibodies. Strong neutralizing antibody responses may require more extensive
271	affinity maturation, which is detected more in COVID-19 patients with severe disease symptoms
272	[27, 31, 32]. Therefore, it is possible that the inability to detect antibodies in RT-PCR-positive
273	subjects may be due to an infection insufficient of magnitude or durability [33]. Another
274	possibility can be that the RT-PCR-positive/antibody-negative subjects had high Ct values at the
275	limit of detection for the assay and did not actually contract the SARS-CoV-2 virus. One study
276	showed there is reduced probability of cultivable viral cultures from samples with a $Ct > 24$ or
277	when samples are obtained >8 days after symptom onset [34], and another study showed Ct
278	values above 33-34 were not associated with cell culture viral recovery [35]. The developed
279	ELISA for all Ig classes against S protein and RBD antigens has a sensitivity of 97.1% after
280	removal of these 17 subjects with indeterminate test results from analysis.

281	Two subjects enrolled in this study were categorized as RT-PCR-negative based on a
282	second RT-PCR test. Their initial RT-PCR test was positive, but retested RT-PCR-negative
283	within 1-2 days after the first result due to the initial test having a high Ct value positive result
284	without any symptoms or contact history. It is possible that some of the RT-PCR-
285	positive/antibody-negative subjects with high Ct values, would have tested negative in a repeated
286	RT-PCR test as well. A study showing repeat testing of the same subjects describes 6.8% of
287	participants who initially test positive, tested negative in a follow-up RT-PCR test [36].
288	Repeating tests can reduce false-positive results, especially in those who have minimal indicators
289	for having been infected. Another way to distinguish possible false-positive results in the RT-
290	PCR is to use a combination of RT-PCR testing and antibody testing to improve the accuracy of
291	COVID-19 diagnosis. One study utilizing rapid antigen diagnostic tests in combination with
292	IgM/IgG detection, identified more subjects with COVID-19 admitted in an emergency
293	department than when the assays are performed separately [37].
294	Conversely, SARS-CoV-2 antibodies were detected in three (5.5%) subjects in the cohort
295	who tested RT-PCR-negative. Detection of SARS-CoV-2 antibodies in these samples may be a
296	result of cross-reactivity of the antibodies with seasonal coronaviruses from previous infections
297	[38, 39]. In the pre-COVID-19 samples (n=520), 11 (2.1%) had cross-reactivity to the SARS-
298	CoV-2 antigens. Additionally, one of the three subjects who was RT-PCR-negative and positive
299	for SARS-CoV-2 antibody was tested in the RT-PCR 113 days after initial symptom onset,
300	which is later than the optimal timing since symptom onset for RT-PCR testing, possibly being
301	the reason for a false-negative RT-PCR test. Taking into account the RT-PCR-negative cohort of
302	subjects, we calculate the overall specificity of the in-house ELISA to be 96.7%.

303	Antibody kinetics reported previously in SARS-CoV-2 infected subjects suggest that
304	titers of the virus-specific IgG and IgM antibodies increase 21 days post symptom onset [18, 40].
305	However, other studies indicate conflicting evidence on whether IgG and neutralizing antibody
306	levels persist or begin to decline in a high proportion of recovered subjects within 2-3 months
307	after infection [18]. Our study found that IgM positivity was lower than that of IgG after
308	infection [18, 38, 41, 42]. Minimal differences were also observed in the percentage of anti-S
309	protein and anti-RBD present in participants drawn at various times over a 3-month period.
310	Furthermore, anti-SARS-CoV-2 antibodies could be found in the circulation of some resolved
311	subjects 200 days post-symptom onset. Resolved subjects who were asymptomatic but RT-PCR-
312	positive, had the lowest titre of SARS-CoV-2 antibodies.

Our study used whole live SARS-CoV-2 viruses in the neutralization assay which was 313 314 able to determine the functional inhibitory capacity of antibodies against all antigens of SARS-315 CoV-2. Neutralizing antibody titres have recently been shown to wane fairly rapidly in some 316 studies and levels were found to be variable in recovered subjects [19, 21, 43-45]. The U.S. Food 317 and Drug Administration (FDA) recommends that the titer of neutralizing antibodies in 318 convalescent plasma should be at least 1/160, but a 1/80 titer is acceptable in the absence of a 319 better match for use in convalescent plasma therapy [46]. Most resolved COVID-19 subjects were found to have developed levels of SARS-CoV-2-specific neutralizing antibodies similar to 320 321 other cross-sectional studies [19, 44, 45]. Neutralizing SARS-CoV-2 antibodies correlated best 322 with a positive anti-RBD IgG (r = 0.5157) and anti-S protein IgG antibody (r = 0.6010) result. 323 However, at this time we do not know what relevant thresholds of neutralizing antibodies confer 324 protection from infection. Of interest, it has been shown that although Fc-dependent effector 325 functions are required for optimal protection, these are often mediated by non-neutralizing

antibodies [47]. Neutralization assays are performed with serum, and thus it is not possible todefine the relative contribution of each antibody class to neutralizing activity.

328 This study has limitations. Recall bias of dates and symptoms by the study participants 329 may affect the interpretation of timing of virus detection in relation to symptom onset. For 330 asymptomatic cases, the time when infection was acquired is not known. In conclusion, our 331 study suggests that there is a variable antibody response in resolved subjects and a variable 332 reduction in antibody positivity over time. The negative antibody results found in the SARS-333 CoV-2 ELISA in RT-PCR-positive samples may suggest a varied immune response that warrants 334 further studies. Although serologic tests cannot be used as the primary diagnostic test, they may 335 be used to support diagnosis of COVID-19 for persons who are tested later, outside the optimal 336 RT-PCR window. The resolved subjects collected for this study are part of a larger longitudinal 337 study that will provide further insight on antibody prevalence over time. Further studies with this 338 longitudinal cohort will be critical in characterizing the nature and kinetics of SARS-CoV-2 339 antibodies and their ability to confer long-term immunity.

341 Acknowledgements:

- 342 We thank Erjona Kruja for technical assistance. Funding support for this work was provided by
- 343 grants from the Ontario Research Fund (ORF), COVID-19 Rapid Research Fund (#C-191-
- 344 2426729-NAZY) and by the Canadian Institute of Health Research (CIHR)-COVID-19
- 345 Immunity Task Force (CITF; #VR2-173204) awarded to Dr. Ishac Nazy, and Academic Health
- 346 Sciences Organization (HAHSO) grant awarded to Dr. Donald M. Arnold (#HAH-21-02). This
- 347 work was also supported, in part, by a Weston Family Microbiome Initiative Grant and a
- 348 Canadian Institute of Health Research (CIHR) COVID-19 Rapid Response grant to Dr. Matthew
- 349 S. Miller. Dr. Miller was also supported, in part, by a CIHR New Investigator Award and an
- 350 Ontario Early Researcher Award. Ali Zhang is supported by a PSI Research Trainee Fellowship
- and a CIHR Canada Graduate Scholarships Doctoral Award. Hannah D. Stacey was supported
- in part by an Ontario Graduate Scholarship.

353 Cell Lines:

- 354 SARS-CoV-2/SB3-TYAGNC strain information: <u>https://wwwnc.cdc.gov/eid/article/26/9/20-</u>
 355 <u>1495_article</u>
- **356 Authorship Contributions:**

357 AH carried out the described studies, analyzed data, and wrote the manuscript. DMA designed

the research and helped write the manuscript. JWS and AZ carried out the described studies,

- analyzed data, and wrote the manuscript. JCM assisted with experimentation, provided technical
- assistance, and helped write the manuscript. VTC provided technical assistance. HDS and JCA
- 361 provided technical assistance and materials. ZC, BJH, RC, NI, DMEB, MSM, and JGK designed

- the research and helped write the manuscript. IN designed the research, interpreted data and
- 363 wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

- 365 Disclosure of Conflicts of Interest:
- 366 The authors declare no competing financial interests.

367 Figures and Tables:

368 Table 1: Clinical Characteristics of Study Participants


	Pre-COVID-19	Resolved	RT-PCR-
	controls	COVID-19	negative
	(n = 520)	subjects	subjects
		(n = 153)	(n = 55)
Ages (years)	-	18 to 82	20 to 89
		(median=49)	(median=49)
Gender			
Male (%)	-	58 (37.9)	16 (29.1)
Female (%)	-	95 (62.1)	39 (70.9)
Hospitalization Status			
Never hospitalized (%)	-	145 (94.8)	55 (100)
Hospitalized (%)	-	8 (5.2)	0
Sample Collection Dates	-	May 2020 – N	lovember 2020
SARS-CoV-2 RT-PCR positivity			
Positive	-	153	0
Negative	-	0	55
Presence of symptoms			

Symptomatic (%)	-	142 (92.8)	37 (67.3)
Asymptomatic (%)	-	11 (7.2)	18 (32.7)
Days post-symptom onset at	-	19 - 227	7 - 260
collection (days)		(median=130.5)	(median=141.5)

369

		RT-PCR-positive	RT-PCR-negative
		(Resolved, n=153)	(n=55)
	SARS-CoV-2	131/153	3/55
	Antibody positive (%)	85.6	5.5
	SARS-CoV-2	22/153	52/55
	Antibody negative (%)	14.4	94.5
372			
373			
374			

371 Table 2: Cross-sectional analysis of RT-PCR and SARS-CoV-2 Antibody Testing



....

377 Figure 1: Ct values are variable in resolved subjects who test SARS-CoV-2 antibody negative or 378 *positive.* Ct values of a subset of resolved subjects (n=54) were compared to their corresponding SARS-CoV-2 (A) anti-S protein IgG and (B) anti-RBD IgG. (C) Ct values were then compared to 379 380 the subjects' respective time since initial RT-PCR test. (D) Ct values for RT-PCR-positive in antibody-positive and antibody-negative were compared. Values are shown as a ratio of observed 381 optical density to the determined assay cut-off optical density or time since RT-PCR test until 382 383 blood donation compared to absolute Ct values. Red circles indicate resolved samples who were 384 RT-PCR-positive/antibody-negative.





Figure 2: Persistence of SARS-CoV-2 antibodies in resolved subjects based on time of blood collection post-symptom onset. Resolved subjects (n=153) were grouped based on days postsymptom onset showing levels of (A) anti-S protein and anti-RBD IgG, (B) IgA, and (C) IgM displayed as dot plots. Days post-symptom onset are binned in 60-day increments and are compared to asymptomatic resolved subjects. Circles represent anti-S protein antibodies and


- 391 squares represent anti-RBD antibodies. Anti-S protein IgG was found in all resolved participants
- 392 collected between 60 and 120 days (23 of 153 total resolved subjects). In the resolved patients
- 393 collected between 120 and 180 days from symptom onset, there was a decrease in the percentage
- of antibody-positive samples when compared to the previous time bin (55 of 60 samples, 91.7%).
- 395



Level of Neutralization	Asymptomatic (n=11)	Non-hospitalized (n=134)	Hospitalized (n=8)
(54.5%)	(14.9%)		
Below Suggested	3/11	50/134	0
FDA Level	(27.3%)	(37.3%)	
Above Suggested	2/11	64/134	8/8
FDA Level	(18.2%)	(47.8%)	(100%)

399 Figure 3: Neutralizing SARS-CoV-2 antibodies against S protein and RBD in IgG, IgA, and 400 IgM found in variable levels in resolved and RT-PCR-negative study participants. Neutralizing 401 SARS-CoV-2 antibody titers from resolved subjects (n=153) were measured in the 402 microneutralization assay and compared to (A) anti-S protein and (B) anti-RBD IgG antibody 403 levels as measured in the SARS-CoV-2 ELISA. Neutralizing antibody titers are expressed as 404 geometric MNT50 values (y-axis). ELISA values are shown as a ratio of observed optical density 405 to the determined assay cut-off optical density (x-axis). (C) Neutralizing SARS-CoV-2 antibody 406 titers from resolved subjects (n=153) were measured in the microneutralization assay were 407 compared to their days since symptom onset. Values above 1 ratio are considered positive in the 408 SARS-CoV-2 ELISA.

409



412 Figure 4: Comparing anti-SARS-CoV-2 IgG, IgA, and IgM responses to S protein and RBD antigens in asymptomatic, non-hospitalized and hospitalized resolved subjects. (A) Anti-S 413 414 protein IgG, IgA, IgM and (B) anti-RBD IgG, IgA, and IgM of the asymptomatic (n=11), non-415 hospitalized resolved subjects (n=134) and hospitalized resolved subjects (n=8) were profiled 416 using the SARS-CoV-2 ELISA. Values are shown as a ratio of observed optical density to the determined assay cut-off optical density. All hospitalized subjects had detectable anti-S protein 417 IgG, anti-RBD IgG and anti-S protein IgA antibodies in their serum. The levels of anti-S protein 418 419 and anti-RBD IgG (mean OD₄₀₅ ratio) in resolved subjects who were hospitalized were

- 420 significantly higher than the non-hospitalized resolved population. Values above 1 ratio are
- 421 considered positive in the SARS-CoV-2 ELISA. * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005.

423 **References:**

- 424 1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus
- 425 of probable bat origin. Nature **2020**; 579:270-3.
- 426 2. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of
- 427 COVID-19. Nat Med **2020**; 26:672-5.
- 428 3. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based
- 429 mitigation measures influence the course of the COVID-19 epidemic? The Lancet **2020**;
- 430 395:931-4.
- 431 4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of
- 432 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
- 433 Yokohama, Japan, 2020. Euro Surveill **2020**; 25.
- 434 5. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic
- 435 Population. N Engl J Med **2020**; 382:2302-15.
- 436 6. Tabata S, Imai K, Kawano S, et al. Clinical characteristics of COVID-19 in 104 people with
- 437 SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. The
- 438 Lancet Infectious Diseases **2020**.
- 439 7. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a
- 440 model-based analysis. The Lancet Infectious Diseases **2020**; 20:669-77.
- 441 8. He JL, Luo L, Luo ZD, et al. Diagnostic performance between CT and initial real-time RT-
- 442 PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan,
- 443 China. Respir Med **2020**; 168:105980.
- 444 9. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA
- 445 **2020**.

- 446 10. Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-
- 447 nCoV) Causing an Outbreak of Pneumonia. Clin Chem **2020**; 66:549-55.
- 448 11. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by
- 449 real-time RT-PCR. Euro Surveill **2020**; 25.
- 450 12. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for
- 451 SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5:562-9.
- 452 13. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the
- 453 prefusion conformation. Science **2020**; 367:1260-3.
- 454 14. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and
- 455 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell **2020**; 181:281-92 e6.
- 456 15. Berry JD, Hay K, Rini JM, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster
- 457 independent of repertoire, antigen structure or mAb technology. MAbs **2010**; 2:53-66.
- 458 16. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
- 459 seroconversion in humans. Nat Med **2020**.
- 460 17. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older
- 461 compared with younger adults and binding antibodies are more sensitive than neutralizing
- 462 antibodies in identifying coronavirus-associated illnesses. J Med Virol **2020**; 92:512-7.
- 463 18. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
- 464 COVID-19. Nat Med **2020**; 26:845-8.
- 465 19. Luchsinger LL, Ransegnola BP, Jin DK, et al. Serological Assays Estimate Highly Variable
- 466 SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. J Clin
- 467 Microbiol **2020**; 58.

- 468 20. Okba NMA, Muller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-
- 469 Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020; 26:1478470 88.
- 471 21. Prevost J, Gasser R, Beaudoin-Bussieres G, et al. Cross-Sectional Evaluation of Humoral
- 472 Responses against SARS-CoV-2 Spike. Cell Rep Med 2020; 1:100126.
- 473 22. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
- 474 coronavirus disease 2019. Clin Infect Dis **2020**.
- 475 23. Roost HP, Bachmann MF, Haag A, et al. Early high-affinity neutralizing anti-viral IgG
- 476 responses without further overall improvements of affinity. Proc Natl Acad Sci U S A 1995;
- **477** 92:1257-61.
- 478 24. Chen Z, Zhang L, Qin C, et al. Recombinant modified vaccinia virus Ankara expressing the
- 479 spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective
- 480 neutralizing antibodies primarily targeting the receptor binding region. J Virol **2005**; 79:2678-88.
- 481 25. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A
- 482 Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc
- 483 Microbiol **2020**; 57:e100.
- 484 26. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing
- 485 antibody responses in the three months following SARS-CoV-2 infection in humans. Nat
- 486 Microbiol **2020**; 5:1598-607.
- 487 27. Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing
- 488 antibody responses in COVID-19. Signal Transduct Target Ther **2020**; 5:180.

- 489 28. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4(+) and CD8(+) T cells
- 490 induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol
- **491 2020**; 21:1336-45.
- 492 29. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of
- 493 COVID-19 and SARS, and uninfected controls. Nature **2020**; 584:457-62.
- 494 30. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2
- 495 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell **2020**;
- 496 181:1489-501 e15.
- 497 31. Schultheiss C, Paschold L, Simnica D, et al. Next-Generation Sequencing of T and B Cell
- 498 Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of
- 499 Disease. Immunity **2020**; 53:442-55 e4.
- 500 32. Marklund E, Leach S, Axelsson H, et al. Serum-IgG responses to SARS-CoV-2 after mild
- and severe COVID-19 infection and analysis of IgG non-responders. PLoS One 2020;
- 502 15:e0241104.
- 503 33. Zhao J, Zhao J, Mangalam AK, et al. Airway Memory CD4(+) T Cells Mediate Protective
- 504 Immunity against Emerging Respiratory Coronaviruses. Immunity **2016**; 44:1379-91.
- 505 34. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with
- 506 RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
- 507 Surveill **2020**; 25.
- 508 35. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as
- a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J
- 510 Clin Microbiol Infect Dis **2020**; 39:1059-61.

- 511 36. Gniazdowski V, Morris CP, Wohl S, et al. Repeat COVID-19 Molecular Testing: Correlation
- 512 of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds. Clin Infect Dis 2020.
- 513 37. Veyrenche N, Bollore K, Pisoni A, et al. 2020.
- 514 38. Adams ER, Ainsworth M, Anand R, et al. Antibody testing for COVID-19: A report from
- the National COVID Scientific Advisory Panel. Wellcome Open Research 2020; 5.
- 516 39. Hicks J, Klumpp-Thomas C, Kalish H, et al. Serologic cross-reactivity of SARS-CoV-2 with
- 517 endemic and seasonal Betacoronaviruses. medRxiv 2020.
- 518 40. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-
- 519 19 patients. Proc Natl Acad Sci U S A **2020**; 117:9490-6.
- 520 41. Gao HX, Li YN, Xu ZG, et al. Detection of serum immunoglobulin M and immunoglobulin
- 521 G antibodies in 2019 novel coronavirus infected patients from different stages. Chin Med J
- 522 (Engl) **2020**; 133:1479-80.
- 523 42. Pérez-García F, Pérez-Tanoira R, Romanyk J, Arroyo T, Gómez-Herruz P, Cuadros-
- 524 González J. 2020.
- 43. Lee WT, Girardin RC, Dupuis Ii AP, et al. Neutralizing Antibody Responses in COVID-19
- 526 Convalescent Sera. J Infect Dis 2020.
- 527 44. Wu F, Liu M, Wang A, et al. Evaluating the Association of Clinical Characteristics With
- 528 Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in
- 529 Shanghai, China. JAMA Intern Med **2020**; 180:1356-62.
- 45. Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of clinical serology assay
- performance and neutralising antibody levels in COVID19 convalescents. medRxiv **2020**.
- 532 46. (FDA) USFaDA. Investigational COVID-19 Convalescent Plasma. Guidance for Industry
- 533 **2020**.

- 47. Winkler ES, Gilchuk P, Yu J, et al. Human neutralizing antibodies against SARS-CoV-2
- require intact Fc effector functions for optimal therapeutic protection. Cell **2021**.